| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 5891541 | Bone | 2011 | 13 Pages |
Abstract
⺠Farnesoid X receptor (FXR, NR1H4) is expressed in BMSC and SaOS2 osteoblast-like cells. ⺠FXR agonists increase osteoblastic differentiation through RUNX2 activation. ⺠Bisphosphonates inhibit basal osteoblastic differentiation possibly through suppression of endogenous FXR agonist production. ⺠FXR antagonist interferes with osteoblastic differentiation and stimulates the expression of adipose tissue markers. ⺠FXR may be involved in the modulation of the osteoblast/adipocyte balance.
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Developmental Biology
Authors
Hichame Id Boufker, Laurence Lagneaux, Hussein Fayyad-Kazan, Bassam Badran, Mehdi Najar, Murielle Wiedig, Ghanem Ghanem, Guy Laurent, Jean-Jacques Body, Fabrice Journé,